国家基本药物目录遴选循证决策路径设计  

Design of Evidence-Based Decision-Making Pathway for the Selection of the National Essential Medicines List

作　　者：张海力 曹文杰 杨一玖 王巍力 梁宁 胡紫腾 刘斌 晏利姣 李慧珍 龚照元 赵国桢 王燕平[1] 史楠楠[1] Zhang Haili;Cao Wenjie;Yang Yijiu(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing,100700,China;不详)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700

出　　处：《中国卫生经济》2025年第1期15-19,共5页Chinese Health Economics

基　　金：中国中医科学院基本科研业务费新入职青年科研人员培养专项(ZZ17-ZRZ-115);国家自然科学基金面上项目(82174532);国家中医药管理局青年岐黄学者培养项目(国中医药人教函[2022] 256号)。

摘　　要：国家基本药物制度可维护人民群众健康,保障公众基本用药权益。当前,我国基本药物目录遴选方法虽然越来越科学规范,但也存在专家经验权重较大、决策依据透明度不足等问题。因此,文章提出建立以临床价值为导向,基于循证决策理念的基本药物遴选路径。该遴选路径具有决策与证据高度耦合的优点,可为我国基本药物目录调整程序和遴选标准优化提供参考和借鉴。The National Essential Medicines System could protect public health and ensure access to essential medications.Although the current selection methods for China's National Essential Medicines Lists(NEMLs) are becoming more scientific and standardized,there are still problems such as much emphasis on expert experience and the lack of transparency of decision-making basis. To address these issues, it proposes an evidence-based decision-making pathway for NEMLs selection guided by clinical value. This approach ensures a strong integration of evidence and decision-making, offering valuable insights for improving the adjustment procedures and selection criteria of the NEMLs in China.

关 键 词：基本药物目录 循证决策 遴选路径 卫生政策 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] R19-0